Open AccessRole of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel disease
Author(s) -
Alessia Di Silvestre,
Marianna Lucafò,
Letizia Pugnetti,
Matteo Bramuzzo,
Gabriele Stocco,
Egidio Barbi,
Giuliana Decorti
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i39.5918
Subject(s) - tristetraprolin , inflammatory bowel disease , phosphorylation , inflammation , medicine , cytokine , immunoprecipitation , immunology , proinflammatory cytokine , tumor necrosis factor alpha , pathogenesis , untranslated region , pathology , disease , messenger rna , biology , antibody , gene , microbiology and biotechnology , biochemistry
Intestinal inflammation and epithelial injury are the leading actors of inflammatory bowel disease (IBD), causing an excessive pro-inflammatory cytokines expression. Tristetraprolin (TTP), an mRNA binding protein, plays a role in regulating the inflammatory factors, recognizing specific sequences on the 3' untranslated region of cytokine mRNAs. TTP activity depends on its phosphorylation state: the unphosphorylated TTP degrades pro-inflammatory cytokine mRNAs; on the contrary, the phosphorylated TTP fails to destabilize mRNAs furthering their expression. The phospho-TTP forms a complex with the chaperone protein 14-3-3. This binding could be one of the factors that promote intestinal inflammation as a cause of disease progression.